Janux Therapeutics enters cancer drug collaboration with Bristol Myers Squibb
Janux Therapeutics announced a major oncology collaboration with Bristol Myers Squibb on Thursday. The deal includes significant upfront and milestone payments.
Insights:
On January 22, 2026, Janux Therapeutics announced that it has entered into a collaboration agreement with Bristol Myers Squibb to develop a new cancer treatment for solid tumors. These tumors are cancers that form masses in organs such as the lung, breast, colon, or pancreas. Following the announcement, Janux Therapeuticsshares rose more than 12% in premarket trading, indicating a positive reception from investors regarding the strategic partnership.
